Regeneron Pharmaceuticals, Inc.
Dosing Strategy that Mitigates Cytokine Release Syndrome for Therapeutic Antibodies

Abstract:

Administration regimens for therapeutic proteins (e.g., T cell-activating bispecific antibodies) that mitigate cytokine release syndrome and infusion-related reaction are disclosed. The methods employ initial fractional dosing with optional administration of additional agents such as steroids or cytokine antagonists that are discontinued with maximal weekly dosing over the course of the dosing regimen.